Hollander David
SEC insider (Form 3/4/5 filer). CIK 0001793796. Chief R&D Officer at Veradermics, Inc (MANE) and 2 other issuers. 6 reported Form 4/5 transactions since Sep 2024; latest on Sep 1, 2026. Located in NEW HAVEN, CT.
Companies Hollander David has filed insider reports for
- Veradermics, Inc (MANE): Officer, Chief R&D Officer
- KIORA PHARMACEUTICALS INC (KPRX): Director
- Revance Therapeutics, Inc. (RVNC): Officer, CMO & Global Therapeutics Lead
Hollander David
CIK: 0001793796
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Sep 1, 2026MANE
Veradermics, Inc
AwardDirect9.7K shares- - Jun 10, 2026KPRX
KIORA PHARMACEUTICALS INC
AwardDirectStock Option (right to buy)
25K shares- - Apr 1, 2025KPRX
KIORA PHARMACEUTICALS INC
AwardDirectStock Option (right to buy)
20K shares- - Feb 6, 2025RVNC
Revance Therapeutics, Inc.
DispositionDirect95.2K shares- - Feb 4, 2025RVNC
Revance Therapeutics, Inc.
Tender OfferDirect9.7K shares at avg. $3.65$36K - Nov 18, 2024RVNC
Revance Therapeutics, Inc.
SaleDirect3.9K shares at avg. $4.17$16K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 1, 2026 |  MANE Veradermics, Inc | Award | 9,650 | - | $0 | Direct |
| Jun 10, 2026 |  KPRX KIORA PHARMACEUTICALS INC | Award Stock Option (right to buy) | 25,000 | - | - | Direct |
| Apr 1, 2025 | KPRX KIORA PHARMACEUTICALS INC | Award Stock Option (right to buy) | 20,000 | - | - | Direct |
| Feb 6, 2025 |  RVNC Revance Therapeutics, Inc. | Disposition | 95,212 | - | - | Direct |
| Feb 4, 2025 | RVNC Revance Therapeutics, Inc. | Tender Offer | 9,733 | $3.65 | $35,525 | Direct |
| Nov 18, 2024 | RVNC Revance Therapeutics, Inc. | Sale | 3,908 | $4.17 | $16,296 | Direct |
1-6 of 6 transactions